Phospho-GRIN2B (Tyr1336) Antibody

What is the Phospho-GRIN2B (Tyr1336) antibody and what does it detect?

Phospho-GRIN2B (Tyr1336) antibody is a rabbit polyclonal antibody that specifically recognizes the NMDA receptor subunit 2B (also known as GluN2B, NMDAR2B, or NR2B) only when phosphorylated at tyrosine residue 1336. This antibody is designed to detect endogenous levels of the NMDA Epsilon 2 protein specifically in its phosphorylated state at Tyr1336 . The antibody does not bind to the unphosphorylated form of the protein, making it a valuable tool for studying this specific post-translational modification.

These antibodies are typically produced by immunizing rabbits with synthetic phospho-peptides corresponding to amino acid residues surrounding Tyr1336 of GRIN2B, often conjugated to carrier proteins like KLH (Keyhole Limpet Hemocyanin) to enhance immunogenicity . The resulting antiserum is then affinity-purified using epitope-specific immunogen to ensure high specificity for the phosphorylated form of the protein .

What experimental applications is the Phospho-GRIN2B (Tyr1336) antibody validated for?

Phospho-GRIN2B (Tyr1336) antibodies are validated for multiple experimental applications in neuroscience research:

• Western Blot (WB): Typically used at dilutions ranging from 1:500 to 1:2000, these antibodies can detect the approximately 180 kDa GRIN2B subunit when phosphorylated at Tyr1336 in tissue or cell lysates . Phospho-specificity can be demonstrated through lambda phosphatase treatment controls, which eliminate immunolabeling .

• Immunohistochemistry (IHC): Usually employed at dilutions of 1:100 to 1:400, these antibodies can visualize the spatial distribution of phosphorylated GRIN2B in tissue sections .

• Immunofluorescence (IF): At dilutions of 1:50 to 1:200, these antibodies can be used for fluorescent detection in fixed cells or tissue sections .

• ELISA: Particularly in cell-based ELISA formats, these antibodies can quantitatively measure phosphorylation levels of GRIN2B at Tyr1336 .

The reactivity of these antibodies typically covers human, mouse, and rat samples, making them versatile tools for both clinical and basic research involving these species .

What is the biological significance of GRIN2B Tyr1336 phosphorylation?

Phosphorylation of GRIN2B at Tyr1336 plays a critical role in regulating NMDA receptor trafficking and localization. Unlike phosphorylation at Tyr1472, which stabilizes NMDA receptors at the synaptic plasma membrane, phosphorylation at Tyr1336 by the tyrosine kinase Fyn has been associated with enrichment of GluN2B-containing receptors in extrasynaptic membranes . This differential phosphorylation creates a molecular switch that determines whether NMDA receptors predominantly localize to synaptic or extrasynaptic sites.

The distinction between synaptic and extrasynaptic NMDA receptors is functionally significant. Synaptic NMDARs are directly involved in excitatory neurotransmission, synaptic plasticity, and pro-survival signaling pathways . In contrast, extrasynaptic NMDARs (enriched when Tyr1336 is phosphorylated) have been associated with loss of mitochondrial membrane potential and cell death pathways when chronically activated .

This phosphorylation-dependent localization represents a key regulatory mechanism for controlling NMDA receptor function and downstream signaling, with important implications for both normal neurophysiology and pathological conditions such as excitotoxicity and neurodegeneration.

How can I confirm the specificity of Phospho-GRIN2B (Tyr1336) antibody in my experiments?

Confirming antibody specificity is crucial for reliable phosphorylation studies. Several approaches are recommended:

• Phosphatase Treatment Control: Treatment of duplicate samples with lambda phosphatase before immunoblotting should abolish detection if the antibody is truly phospho-specific. Western blot data shows complete elimination of the ~180 kDa band following lambda phosphatase treatment (1200 units for 30 minutes) .

• Peptide Competition Assay: Pre-incubating the antibody with the phosphorylated peptide immunogen should block detection, while pre-incubation with the non-phosphorylated version of the same peptide should not affect signal intensity.

• Genetic Controls: Samples from GRIN2B knockout models or cells treated with GRIN2B-specific siRNA should show absence of signal.

• Tyrosine Kinase Inhibitor Treatment: Cells treated with Fyn inhibitors should show decreased signal intensity, as Fyn is the primary kinase responsible for phosphorylating Tyr1336 .

• Mutation Studies: In recombinant expression systems, comparing wild-type GRIN2B with Y1336F mutants (where tyrosine is replaced with non-phosphorylatable phenylalanine) can provide definitive evidence of antibody specificity.

Each of these controls addresses different aspects of antibody specificity and should be selected based on the experimental context and available resources.

What are the optimal sample preparation protocols for detecting Phospho-GRIN2B (Tyr1336)?

Optimal sample preparation is critical for preserving phosphorylation status and achieving robust detection:

For Western Blotting:

• Rapidly harvest tissues or cells in ice-cold conditions to prevent phosphatase activity

• Use lysis buffers containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) and protease inhibitors

• Include EDTA (1-5 mM) to chelate metal ions required for phosphatase activity

• Maintain samples at 4°C during processing

• Consider adding 1% SDS to the lysis buffer for complete solubilization of membrane proteins

• Use fresh samples when possible, as freeze-thaw cycles can degrade phospho-epitopes

For Immunohistochemistry/Immunofluorescence:

• Perfuse animals with phosphate-buffered saline containing phosphatase inhibitors prior to fixation

• Use 4% paraformaldehyde for fixation, avoiding methanol which can disrupt phospho-epitopes

• Include phosphatase inhibitors in all washing and blocking buffers

• Consider antigen retrieval methods optimized for phospho-epitopes (citrate buffer pH 6.0)

• Block with 5-10% normal serum from the species of the secondary antibody

For Cell-Based ELISA:

• Seed cells at consistent density (typically >5000 cells per well) for reproducible results

• Stimulate cells with appropriate agonists/antagonists in serum-free media to minimize background

• Fix cells with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100

• Include both phospho-specific and total GRIN2B antibody controls

Proper sample preparation significantly improves detection sensitivity and experimental reproducibility for phospho-specific analyses.

How should I optimize Western blot protocols for Phospho-GRIN2B (Tyr1336) detection?

Western blot detection of Phospho-GRIN2B (Tyr1336) requires special considerations:

• Sample Preparation:

  • Use fresh tissue/cell lysates when possible

  • Include 1-2 mM sodium orthovanadate in lysis buffer

  • Heat samples at 70°C (not 95°C) for 5 minutes to prevent aggregation of this large membrane protein

• Gel Electrophoresis:

  • Use low percentage (6-8%) SDS-PAGE gels to resolve the ~180 kDa GRIN2B protein

  • Consider gradient gels (4-15%) for better resolution

  • Load adequate protein (50-100 μg per lane) from neural tissues

• Transfer Conditions:

  • Use wet transfer rather than semi-dry methods

  • Transfer at lower voltage (30V) overnight at 4°C

  • Add 0.1% SDS to transfer buffer to aid in moving large proteins

• Antibody Incubation:

  • Block with 5% BSA (not milk) in TBST to prevent phosphatase activity

  • Use recommended dilutions (1:500-1:2000) in 5% BSA in TBST

  • Incubate with primary antibody overnight at 4°C

  • Use TBS rather than PBS for all wash steps (phosphate can interfere with phospho-detection)

• Detection:

  • Use highly sensitive ECL substrates for optimal detection

  • Consider fluorescent secondary antibodies for quantitative analysis

  • Include positive control samples (brain tissue lysate) and molecular weight markers

• Controls:

  • Run parallel blots with antibodies against total GRIN2B for normalization

  • Include lambda phosphatase-treated samples as negative controls

These optimizations help overcome the technical challenges associated with detecting phosphorylated forms of large, relatively low-abundance membrane proteins like GRIN2B.

How can Phospho-GRIN2B (Tyr1336) antibodies be used to study NMDA receptor trafficking?

Phospho-GRIN2B (Tyr1336) antibodies provide valuable tools for investigating NMDA receptor trafficking between synaptic and extrasynaptic compartments:

• Subcellular Fractionation Studies: By separating postsynaptic density (PSD) fractions from non-PSD membrane fractions, researchers can quantify the relative abundance of Tyr1336-phosphorylated GRIN2B in each compartment using Western blotting. This approach can reveal how various stimuli or disease states alter receptor localization.

• Immunofluorescence Co-localization: Double-labeling with Phospho-GRIN2B (Tyr1336) antibodies and markers of synaptic sites (e.g., PSD-95) versus extrasynaptic membranes can visualize the spatial distribution of phosphorylated receptors. Research has shown that Tyr1336 phosphorylation correlates with reduced co-localization with PSD-95, supporting its role in extrasynaptic localization .

• Live-Cell Imaging: When combined with overexpression of fluorescently-tagged GRIN2B constructs and site-directed mutagenesis (Y1336F), these antibodies can be used in internalization assays to track the movement of receptors following stimulation.

• Proximity Ligation Assays (PLA): This technique can detect interactions between phosphorylated GRIN2B and trafficking proteins with single-molecule sensitivity in intact cells.

• Quantitative Cell-Surface Biotinylation: By comparing surface versus internal pools of phosphorylated GRIN2B, researchers can determine how Tyr1336 phosphorylation affects membrane insertion and internalization rates.

These approaches help elucidate the molecular mechanisms by which phosphorylation regulates NMDA receptor distribution, a process fundamentally important to synaptic plasticity and excitotoxicity.

What is the relationship between GRIN2B Tyr1336 phosphorylation and neurological disorders?

The phosphorylation of GRIN2B at Tyr1336 has significant implications for neurological disorders, particularly those involving excitotoxicity:

• Stroke and Ischemic Injury: Experimental evidence suggests that cerebral ischemia increases Fyn kinase activity, potentially enhancing Tyr1336 phosphorylation and promoting accumulation of extrasynaptic NMDA receptors. Since extrasynaptic NMDA receptors are linked to cell death pathways, this phosphorylation event may exacerbate neuronal damage following stroke .

• Neurodegenerative Diseases: In Alzheimer's disease models, altered NMDA receptor trafficking and increased extrasynaptic localization have been observed. Investigations using Phospho-GRIN2B (Tyr1336) antibodies can help determine whether aberrant phosphorylation contributes to these changes.

• Excitotoxicity Mechanisms: The phosphorylation at Tyr1336 by Fyn enriches GluN2B-containing receptors in extrasynaptic membranes, potentially making neurons more vulnerable to glutamate-induced excitotoxicity. Chronic activation of these extrasynaptic receptors leads to loss of mitochondrial membrane potential, an early marker for glutamate-induced neuronal damage .

• Therapeutic Implications: Understanding the regulation of Tyr1336 phosphorylation could lead to novel therapeutic strategies. Rather than blocking all NMDA receptors (which has proven problematic in clinical trials), selectively targeting receptor trafficking by modulating phosphorylation might provide better therapeutic outcomes.

• Biomarker Potential: Altered levels of Tyr1336 phosphorylation in accessible samples (CSF, exosomes) might serve as biomarkers for disease progression or treatment response.

Research using Phospho-GRIN2B (Tyr1336) antibodies continues to illuminate the role of this post-translational modification in neurological disease mechanisms and potential therapeutic interventions.

How does Phospho-GRIN2B (Tyr1336) compare with other phosphorylation sites on GRIN2B?

GRIN2B contains multiple phosphorylation sites that differentially regulate receptor function and localization:

The interplay between these different phosphorylation sites creates a complex regulatory network:

• Opposing Trafficking Effects: While Tyr1336 phosphorylation promotes extrasynaptic localization, Tyr1472 phosphorylation has the opposite effect, stabilizing NMDA receptors at synaptic sites through interaction with the AP-2 adaptor complex and PSD-95 .

• Sequential Phosphorylation: Evidence suggests that these sites may be phosphorylated in a sequential or coordinated manner, potentially creating a phosphorylation "code" that dictates receptor fate.

• Stimulus-Specific Regulation: Different patterns of neuronal activity may preferentially activate specific kinases, leading to distinct phosphorylation patterns and functional outcomes.

• Interactions with Other Modifications: Phosphorylation at these sites may interact with other post-translational modifications such as ubiquitination to regulate receptor degradation versus recycling.

Understanding the relative balance of phosphorylation at these different sites is critical for interpreting experimental results and developing targeted interventions for neurological disorders.

What are common challenges when using Phospho-GRIN2B (Tyr1336) antibodies and how can they be addressed?

Researchers commonly encounter several challenges when working with Phospho-GRIN2B (Tyr1336) antibodies:

• Low Signal Intensity:

  • Problem: GRIN2B is expressed primarily in neurons and phosphorylation is a dynamic, often substoichiometric modification.

  • Solution: Increase protein loading (50-100 μg), use more sensitive detection methods, enrich for membrane fractions, immunoprecipitate before Western blotting, or use phosphatase inhibitors throughout sample preparation.

• High Background:

  • Problem: Non-specific binding, particularly in immunohistochemistry applications.

  • Solution: Extend blocking time (2-3 hours), use alternative blocking reagents (e.g., fish gelatin instead of BSA), increase antibody dilution, include 0.1% Triton X-100 in wash buffers, and extend washing steps.

• Poor Reproducibility:

  • Problem: Phosphorylation status is highly sensitive to sample handling.

  • Solution: Standardize tissue collection procedures, minimize time between sacrifice and freezing, use consistent lysis buffers with fresh phosphatase inhibitors, and maintain samples at 4°C throughout processing.

• Multiple Bands in Western Blots:

  • Problem: Detection of splice variants, degradation products, or cross-reactivity.

  • Solution: Verify band size (~180 kDa for full-length GRIN2B), include negative controls, and perform peptide competition assays to confirm specificity.

• Variability Between Antibody Lots:

  • Problem: Different production batches may have varying specificity profiles.

  • Solution: Validate each new lot against previous lots, request certificates of analysis from vendors, and maintain internal positive control samples.

• Limited Tissue Penetration in IHC:

  • Problem: Poor antibody penetration in thick tissue sections.

  • Solution: Optimize antigen retrieval methods, increase incubation time (24-48 hours at 4°C), use lower antibody concentrations for longer periods, or consider tissue clearing techniques for thick sections.

Addressing these challenges requires careful optimization for each specific application and experimental system.

How should I design experiments to study the dynamic regulation of GRIN2B Tyr1336 phosphorylation?

Designing experiments to capture the dynamic regulation of Tyr1336 phosphorylation requires careful consideration of temporal and spatial aspects:

• Time-Course Studies:

  • Design experiments with multiple time points following stimulation (e.g., glutamate treatment, NMDA application, synaptic activity modulation)

  • Include both short (seconds to minutes) and long (hours) time points to capture both acute and adaptive changes

  • Use rapid quenching of phosphatase activity at each time point to preserve phosphorylation status

• Pharmacological Manipulations:

  • Use specific Fyn kinase inhibitors (e.g., PP2) to block phosphorylation

  • Apply phosphatase inhibitors (e.g., okadaic acid, calyculin A) to enhance detection

  • Employ synaptic versus extrasynaptic NMDA receptor activation protocols (e.g., bicuculline + 4-AP for synaptic; low Mg²⁺ + TTX for extrasynaptic)

• Spatial Analysis:

  • Combine subcellular fractionation with Western blotting to track movement between compartments

  • Use super-resolution microscopy with Phospho-GRIN2B (Tyr1336) antibodies to visualize nanoscale distribution

  • Employ proximity ligation assays to detect interactions with trafficking partners

• Genetic Approaches:

  • Use CRISPR/Cas9 to generate Y1336F knock-in mutations in cellular or animal models

  • Create phosphomimetic mutations (Y1336E) to study the effects of constitutive phosphorylation

  • Employ inducible expression systems to control the timing of wild-type versus mutant GRIN2B expression

• Quantitative Techniques:

  • Use cell-based ELISA systems for high-throughput screening of conditions affecting phosphorylation

  • Employ phospho-specific flow cytometry for single-cell analysis

  • Consider mass spectrometry approaches to quantify phosphorylation stoichiometry

• Physiological Contexts:

  • Study phosphorylation in response to learning paradigms in vivo

  • Examine changes during development and aging

  • Investigate alterations in disease models (stroke, neurodegenerative conditions)

These approaches can be combined to provide comprehensive insights into the regulation and functional significance of GRIN2B Tyr1336 phosphorylation.

How can Phospho-GRIN2B (Tyr1336) antibodies be utilized in high-throughput screening applications?

Phospho-GRIN2B (Tyr1336) antibodies can be effectively integrated into high-throughput screening (HTS) platforms to identify modulators of NMDA receptor trafficking and function:

• Cell-Based ELISA Screens: The NMDAR2B (Phospho-Tyr1336) Colorimetric Cell-Based ELISA Kit provides a convenient, lysate-free, high-throughput assay system for measuring relative phosphorylation levels in cultured cells . This format is particularly valuable for screening:

  • Small molecule libraries for compounds that modulate Fyn kinase activity

  • Natural product collections for novel NMDA receptor trafficking regulators

  • siRNA/shRNA libraries to identify genes involved in phosphorylation regulation

• Automated Microscopy Platforms: High-content imaging systems can be used with Phospho-GRIN2B (Tyr1336) antibodies to simultaneously assess:

  • Phosphorylation levels

  • Subcellular localization

  • Co-localization with synaptic markers

  • Neuronal morphology and viability

• Phospho-Flow Cytometry: Adaptation of Phospho-GRIN2B detection to flow cytometry enables:

  • Single-cell analysis of phosphorylation heterogeneity

  • Multiparameter assessment with other signaling markers

  • Rapid screening of thousands of conditions

• Biosensor Development: Phospho-specific antibodies can be incorporated into FRET-based biosensors to monitor phosphorylation dynamics in real-time within living cells.

• Phosphoproteomics Integration: Antibody-based enrichment of phosphorylated GRIN2B can enhance detection sensitivity in mass spectrometry-based phosphoproteomic screens, allowing quantification of multiple phosphorylation sites simultaneously.

These high-throughput approaches accelerate the discovery process and enable identification of context-specific regulators that might be missed in traditional low-throughput experiments.

What is the potential for using Phospho-GRIN2B (Tyr1336) as a biomarker in neurological disorders?

The use of Phospho-GRIN2B (Tyr1336) as a biomarker in neurological disorders shows promise for several applications:

• Diagnostic Applications:

  • Altered phosphorylation patterns might distinguish different pathological processes

  • Detection in cerebrospinal fluid (CSF) could potentially indicate ongoing excitotoxic damage

  • Changes in phosphorylation ratio (pTyr1336/total GRIN2B) may correlate with disease stage

• Prognostic Indicators:

  • In acute brain injuries (stroke, TBI), levels of phosphorylation might predict extent of secondary damage

  • Baseline phosphorylation patterns could identify patients at higher risk for excitotoxicity

  • Longitudinal monitoring might track disease progression in neurodegenerative conditions

• Treatment Response Monitoring:

  • Changes in phosphorylation following treatment might serve as pharmacodynamic markers

  • Early shifts in phosphorylation could predict later clinical outcomes

  • Rapid assessment of target engagement for drugs affecting NMDA receptor trafficking

• Challenges in Biomarker Development:

  • Limited accessibility of CNS tissue necessitates development of surrogate markers

  • Phosphorylation states are highly dynamic and sensitive to sample handling

  • Standardization of collection and processing protocols is essential

  • Baseline variability in different populations must be established

• Emerging Approaches:

  • Analysis of phosphorylation in neuronal exosomes isolated from blood or CSF

  • Development of PET ligands that selectively bind phosphorylated forms

  • Integration with other biomarkers in multiparameter panels

While still in early development, the biological significance of Tyr1336 phosphorylation in regulating excitotoxicity pathways makes it a compelling candidate for biomarker research in conditions characterized by neuronal damage.